Insitro aims to improve the drug discovery process. Founded by machine-learning veteran Daphne Koller, it creates in vitro models of human disease in its automated laboratory and then applies machine-learning models to predict possible effective therapies. It recently announced a partnership with drug maker Gilead Sciences, worth up to $1 billion, to help it find a treatment for a form of liver disease called nonalcoholic steatohepatis, or NASH.
insitro
Unlock to Claim this listing
Add / Modify Company
Click to rate this company
[Total: 0 Average: 0]
Click here to sign in to vote
1.55
Overall Excellence Rating
Industry
Pharmaceuticals & BiotechnologyCategory
BiotechnologyESG/Ethical Impact
Insitro actively engages with local communities through partnerships with healthcare organizations, educational initiatives, and outreach programs that promote scientific education and social growth. We prioritize advancing healthcare by developing innovative solutions that improve patient outcomes, expand access to treatments, and contribute to the overall well-being of society. Insitro champions diversity and inclusion, recognizing the value of diverse perspectives in scientific discovery and fostering a culture of equity and inclusion within our organization. Ethical sourcing is integral to our operations, with rigorous supplier vetting processes to ensure ethical practices and sustainability standards in the procurement of research materials.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer.

Awards Received
2023
Revenues
7500000.00
Website Traffic
Employee Rating
3.50
Customer Rating
Company Size
100-1000
ESG Risk Rating
3.00
We’re Happy to Help.
Do you have questions about your ranking, our projects, or why you’re not on the list?